

Appendix 3: List of reviewed papers in alphabetical order

- Artemiadis AK, Vervainioti AA, Alexopoulos EC, *et al.* Stress management and multiple sclerosis: a randomized controlled trial. *Arch Clin Neuropsychol* 2012;27:406-416.
- Bansi J, Bloch W, Gamper U, *et al.* Endurance training in MS: short-term immune responses and their relation to cardiorespiratory fitness, health-related quality of life, and fatigue. *J Neurol* 2013;260:2993-3001.
- Bansi J, Bloch W, Gamper U, *et al.* Training in MS: influence of two different endurance training protocols (aquatic versus overland) on cytokine and neurotrophin concentrations during three week randomized controlled trial. *Mult Scler J* 2012;19:613-621.
- Baron KG, Corden M, Jin L, *et al.* Improvement in insomnia with psychotherapy for depression in patients with multiple sclerosis. *J Behav Med* 2011;34:92-101.
- Bastani F, Sobhani M, and Ghasemi HSE. Effect of acupuncture on fatigue in women with multiple sclerosis. *Global J Health Sci* 2015;7.
- Beckner V, Howard I, Vella L, *et al.* Telephone-administered psychotherapy for depression in MS patients: moderating role of social support. *J Behav Med* 2010;33:47-59.
- Blackmore DE, Hart SL, Albani JJ, *et al.* Improvements in partner support predict sexual satisfaction among individuals with multiple sclerosis. *Rehabil Psychol* 2011;56:117-122.
- Collett J, Dawes H, Meaney A, *et al.* Exercise for multiple sclerosis: a single-blind randomized trial comparing three exercise intensities. *Mult Scler J* 2010;17:594-603.
- Collin C, Davies P, Mutiboko IK, *et al.* Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. *Eur J Neurol* 2007;14:290-296.
- Cosio D, Jin L, Siddique J, *et al.* The effect of telephone-administered cognitive-behavioral therapy on quality of life among patients with multiple sclerosis. *Ann Behav Med* 2011;41:227-234.
- Dodd KJ, Taylor NF, Shields N, *et al.* Progressive resistance training did not improve walking but can improve muscle performance, quality of life and fatigue in adults with multiple sclerosis: a randomized controlled trial. *Mult Scler* 2011;17:1362-1374.
- Freeman RM, Adekanmi O, Waterfield MR, *et al.* The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). *Int Urogynecol J* 2006;17:636-641.
- Gandolfi M, Munari D, Geroi C, *et al.* Sensory integration balance training in patients with multiple sclerosis: a randomized, controlled trial. *Mult Scler J* 2015;21:1453-1462.
- Garrett M, Hogan N, Larkin A, *et al.* Exercise in the community for people with minimal gait impairment due to MS: an assessor-blind randomized controlled trial. *Mult Scler J* 2012b;19:782-789.
- Grossman P, Kappos L, D'Souza M, *et al.* MS quality of life, depression, and fatigue improves after mindfulness training. *Neurol* 2010;75:1141-1149.
- Hart SL, and Mohr DC. Relationships among depressive symptoms, benefit-finding, optimism, and positive affect in multiple sclerosis patients after psychotherapy for depression. *Health Psychol* 2008;27:230-238.

Hughes CM, Smyth S, and Lowe-Strong AS. Reflexology for the treatment of pain in people with multiple sclerosis: a double-blind randomised sham-controlled clinical trial. *Mult Scler* 2009;15:1329-1338.

Kampman MT, Steffensen LH, Mellgren SI, et al. Effects of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. *Mult Scler J* 2012;18:1144-1151.

Knoop H, van Kessel K, and Moss-Morris R. Which cognitions and behaviours mediate the positive effect of cognitive behavioural therapy on fatigue in patients with multiple sclerosis? *Psychol Med* 2012;42:205-213.

Lincoln NB, Yuill F, Holmes J, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. *Mult Scler J* 2011;17:1250-1257.

Lovera JF, Kim E, Heriza E, et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial. *Neurol* 2012;79:1278-1284.

Mohr DC, Hart S, and Vella L. Reduction in disability in a randomized controlled trial of telephone-administered cognitive-behavioral therapy. *Health Psychol* 2007;26:554-563.

Mohr DC, Hart SL, Julian L, et al. Telephone-administered psychotherapy for depression. *Arch Gen Psychiatry* 2005;62:1007-1014.

Mohr DC, Classen C, and Barrera M. The relationship between social support, depression and treatment for depression in people with multiple sclerosis. *Psychol Med* 2004;34:533-541.

Mohr DC, Hart SL, and Goldberg A. Effects of treatment for depression on fatigue in multiple sclerosis. *Psychosomatic Med* 2003;65:542-547.

Mohr DC, Boudewyn AC, and Goodkin DE. Comparative outcomes for individual cognitive-behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. *J Con Clin Psychol* 2001;69:942-949.

Morrow SA, and Rosehart H. Effects of single dose mixed amphetamine salts – extended release on processing speed in multiple sclerosis: a double blind placebo controlled study. *Psychopharmacology* 2015;232:4253-4259.

Mosayebi G, Ghazavi A, Ghasami K, et al. Therapeutic effect of vitamin D3 in multiple sclerosis patients. *Immun Invest* 2011;40:627-639.

Moss-Morris R, Dennison L, Landau S, et al. A randomized controlled trial of cognitive behavioral therapy (CBT) for adjusting to multiple sclerosis (the saMS Trial): does CBT work and whom does it work? *J Consult Clin Psychol* 2013;81:251-262.

Nazari F, Soheili M, Hosseini SM, et al. A comparison of the effects of reflexology and relaxation on pain in women with multiple sclerosis. *J Complement Integr Med* 2016;13:65-71.

Nilsagard YE, Forsberg AS, and von Koch L. Balance exercise for persons with multiple sclerosis using Wii games: a randomised, controlled multi-centre study. *Mult Scler J* 2012;19:209-216.

Novotna A, Mares J, Ratcliffe S, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. *Eur J Neurol* 2011;18:1122-1131.

Oken BS, Kishiyama S, Zajdel D, *et al.* Randomized controlled trial of yoga and exercise in multiple sclerosis. *Neurol* 2004;62:2058-2064.

Rezapour-Firouzi S, Arefhosseini SR, Ebrahimi-Mamaghani M, *et al.* Activity of liver enzymes in multiple sclerosis patients with Hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention. *Complement Ther Med* 2014;22:986-993.

Rezapour-Firouzi S, Arefhosseini SR, Ebrahimi-Mamaghani M, *et al.* Alteration of delta-6-desaturase (FADS2), secretory phospholipase-A2 (sPLA2) enzymes by hot-nature diet with co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. *Complement Ther Med* 2015.

Rezapour-Firouzi S, Arefhosseini SR, Mehdi F, *et al.* Immunomodulatory and therapeutic effects of hot-nature diet and co-supplemented hemp seed, evening primrose oils intervention in multiple sclerosis patients. *Complement Ther Med* 2013;21:473-480.

Rezapour-Firouzi S, Arefhosseini SR, Ebrahimi-Mamaghani M, *et al.* Erythrocyte membrane fatty acids in multiple sclerosis patients and hot-nature dietary intervention with co-supplemented hemp-seed and evening-primrose oils. *Afr J Tradit Complement Altern Med* 2013b;10:519-527.

Rog DJ, Nurmikko TJ, Friede T, *et al.* Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurol* 2005;65:812-819.

Romberg A, Virtanen A, Ruutiainen J, *et al.* Effects of a 6-month exercise program on patients with multiple sclerosis: a randomized study. *Neurol* 2004;63:2034-2038.

Romberg A, Virtanen A, and Ruutiainen J. Long-term exercise improves functional impairment but not quality of life in multiple sclerosis. *J Neurol* 2005;252:839-845.

Rosjo E, Steffensen LH, Jorgensen L, *et al.* Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis. *J Neurol* 2015;262:2713-2721.

Soilu-Hänninen M, Äivo J, Lindström B-M, *et al.* A randomised, double-blind, placebo controlled trial with vitamin D₃ as an add on treatment to interferon β -1b in patients with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2012;83:565-571.

Steffensen LH, Jorgensen L, Straume B, *et al.* Can vitamin D₃ supplementation prevent bone loss in persons with MS? A placebo-controlled trial. *J Neurol* 2011;258:1624-1631.

Straudi S, Fanciullacci C, Martinuzzi C, *et al.* The effects of robot-assisted gait training in progressive multiple sclerosis: a randomized controlled trial. *Mult Scler J* 2016;22:373-384.

Stuifbergen AK, Becker H, Perez F, *et al.* A randomized controlled trial of a cognitive rehabilitation intervention for persons with multiple sclerosis. *Clin Rehabil* 2012;26:882-893.

Tarakci E, Yeldan I, Huseyinsinoglu BE, *et al.* Group exercise training for balance, functional status, spasticity, fatigue and quality of life in multiple sclerosis: a randomized controlled trial. *Clin Rehabil* 2013;27:813-822.

Thomas S, Kersten P, Thomas PW, *et al.* Exploring strategies used following a group-based fatigue management programme for people with multiple sclerosis (FACETS) via the Fatigue Management Strategies Questionnaire (FMSQ). *BMJ Open* 2015;5:e008274.

Thomas PW, Thomas S, Kersten P, *et al.* One year follow-up of a pragmatic multi-centre randomised controlled trial of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. *BMC Neurol* 2014;14:109.

Thomas S, Thomas PW, Kersten P, *et al.* A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2013;84:1092-1099.

Torkildsen T, Wergeland S, Bakke S, *et al.* ω -3 fatty acid treatment in multiple sclerosis (OFAMS study). *Arch Neurol* 2012;69:1044-1051.

Tourbah A, Lebrun-Frenay C, Edan G, *et al.* MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. *Mult Scler J* 2016;22:1719-1731.

van Kessel K, Moss-Morris R, Willoughby E, *et al.* A randomized controlled trial of cognitive behaviour therapy for multiple sclerosis fatigue. *Psychosomatic Med* 2008;70:205-213.

Wade DT, Makela P, Robson P, *et al.* Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. *Mult Scler* 2004;10:434-441.

Zajicek JP, Hobart JC, Slade A, *et al.* Multiple sclerosis and extract of cannabis: results of the MUSEC trial. *J Neurol Neurosurg Psychiatry* 2012;83:1125-1132.

Zajicek JP, Sanders HP, Wright DE, *et al.* Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. *J Neurol Neurosurg Psychiatry* 2005;76:1664-1669.

Zajicek J, Fox P, Sanders H, *et al.* Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet* 2003;362:1517-1526.